stockportfolio.pro
Stocks / BLTE vs RYTM
BLTE vs RYTM
Belite Bio, Inc and Rhythm Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Belite Bio, Inc (BLTE) | Rhythm Pharmaceuticals, Inc. (RYTM) | |
|---|---|---|
| Market cap | $5.5B | $5.9B |
| Revenue (latest FY) | $0 | $189.76M |
| Net income (latest FY) | $-77.61M | $-196.54M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | — | -103.6% |
| Return on equity | -10.1% | -72.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BLTE — free Open RYTM — freeFrequently asked questions
Which is bigger, BLTE or RYTM?
Rhythm Pharmaceuticals, Inc. is larger by market capitalization — $5.9B versus $5.5B.
Which grows faster, BLTE or RYTM?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.